Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKEY6S)

• Drug Name: Margetuximab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
HER2-positive breast cancer	2C60-2C65	Approved	[1]
Gastric adenocarcinoma	2B72	Phase 2	[2] , [3]
Gastrointestinal cancer	2C11	Phase 2	[4] , [5]

• Cross-matching ID: TTD Drug ID: DMKEY6S

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[6]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[7]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[8]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[9]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[10]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[11]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[12]
Pertuzumab	DMHJV0X	Breast cancer	2C60-2C65	Approved	[13]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[14]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8686).
• [5] ClinicalTrials.gov (NCT01828021) Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer. U.S. National Institutes of Health.
• [6] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [8] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [11] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [13] Clinical pipeline report, company report or official report of Roche (2009).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.